Log in to search using one of your social media accounts:

 

Diabetes: Medtronic touts JAMA study of closed-loop artificial pancreas
Medtronic (NYSE:MDT) said data from a study of its closed-loop hybrid artificial pancreas, published in the Journal of the American Medical Assn., showed that the system is safe and effectively maintained blood glucose levels within range in Type I diabetes patients age 14 and older. Results from the 3-month, 124-patient trial, also presented this week at the annual meeting of the European Assn. for the Study of Diabetes in Munich, had safety endpoints of the incidence of severe hypoglycemia and diabetic ketoacidosis, serious adverse events and device-related serious and unanticipated adverse events. Data from the stu...
Source: Mass Device - September 15, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Clinical Trials Diabetes Artificial pancreas Journal of the American Medical Assn. (JAMA) Medtronic Source Type: news

Prevention of Autoantibody-Positive Rheumatoid Arthritis Prevention of Autoantibody-Positive Rheumatoid Arthritis
A new review looks at the potential risk factors that may contribute to the development of rheumatoid arthritis and discusses preventive strategies.Rheumatology (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - September 15, 2016 Category: Allergy & Immunology Tags: Rheumatology Journal Article Source Type: news

Rising PSA Level in an Anxious Postprostatectomy Patient
A 66-year-old Caucasian man with a history of hypertension, hyperlipidemia, and rheumatoid arthritis was diagnosed with prostate cancer. (Source: CancerNetwork)
Source: CancerNetwork - September 15, 2016 Category: Cancer & Oncology Authors: Judd W. Moul, MD Robert Qi Tags: Case Studies Genitourinary Cancers Oncology Journal Prostate Cancer Source Type: news

Price Increases To Help Drug Hit $15 Billion In Sales
AbbVie’s Humira, used to treat rheumatoid arthritis and other autoimmune disorders, could reach $15 billion in annual sales, according to forecasts by the investment bank Leerink.* (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - September 14, 2016 Category: Pharmaceuticals Authors: Matthew Herper Source Type: news

Juvenile Idiopathic Arthritis (Juvenile Rheumatoid Arthritis)
Title: Juvenile Idiopathic Arthritis (Juvenile Rheumatoid Arthritis)Category: Diseases and ConditionsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 9/14/2016 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - September 14, 2016 Category: Rheumatology Source Type: news

Express Scripts Tries to Rein in Pricey Inflammatory Drugs Express Scripts Tries to Rein in Pricey Inflammatory Drugs
Express Scripts Holding, the largest manager of U.S. drug benefits, on Thursday launched a program aimed at tightening spending on drugs for pricey inflammatory conditions such as rheumatoid arthritis.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 9, 2016 Category: Consumer Health News Tags: Family Medicine/Primary Care News Source Type: news

Risk-benefit profile of statin therapy 'may be more positive than expected'
This study showed that providing an effective low-cost statin therapy to 10,000 patients for five years would prevent major cardiovascular events such as heart attacks, strokes and coronary artery bypasses in 1,000 people with preexisting vascular disease, as well as 500 people who are at increased risk but have not yet had a vascular event. By contrast, only 50 to 100 cases of symptomatic adverse events would be expected over the same period, as well as 50 to 100 new cases of diabetes, five cases of myopathy and between five and ten haemorrhagic strokes. Should statins be more widely used? Currently, about six million peo...
Source: Arthritis Research UK - September 8, 2016 Category: Rheumatology Source Type: news

Older rheumatoid arthritis patients 'must take special care over safety of biologics'
Elderly patients with rheumatoidarthritis may require special care when treated with biologics to manage potential safety issues arising from the use of thesedrugs. This is according to a new study led by Keio University School of Medicine in Japan, which has provided evidence that those over the age of 65 may be at greater risk of negative reactions when prescribed biologic therapies. More adverse events leading to treatment withdrawal In order to clarify the safety of biologic therapies in elderly patients withrheumatoid arthritis, the researchers analysed the performance of biologics in relation to age among a cohort of...
Source: Arthritis Research UK - September 6, 2016 Category: Rheumatology Source Type: news

Cardinal Health to pay up to $310m for Navidea ’ s LymphoSeek
Navidea (NYSE:NAVB) said today it inked a letter of intent with Cardinal Health (NYSE:CAH) to sell its Lymphoseek injection for up to $310 million. The sale includes all current FDA-approved indications, as well as future oncology diagnostic indications in North America and other related assets, Dublin, Ohio-based Navidea said. Through the deal, Navidea is slated to receive $80 million upon closing, with future considerations tied to annual sales of Lymphoseek and sales-based milestones. “This is a significant announcement for all of us at Navidea. This agreement with Cardinal Health will provide signi...
Source: Mass Device - September 6, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Diagnostics Mergers & Acquisitions Oncology Cardinal Health Navidea Biopharmaceuticals Source Type: news

I'm a Diabetic, Why is my Shoulder Frozen?
What Is Adhesive Capsulitis? Adhesive capsulitis is a painful, progressive loss of shoulder motion. The shoulder is usually stiff and will not move. This condition is called "frozen shoulder". When a patient presents with adhesive capsulitis, they are unable to move their arm up or turn it to either side either with or without assistance (passive/active range of motion). Typically adhesive capsulitis occurs in approximately 2% of the population and usually affects people 40-60 years of age. Frozen shoulder tends to occur more often in females. The loss of motion occurs due to inflammation, fibrosis, scarring and ...
Source: Healthy Living - The Huffington Post - September 6, 2016 Category: Consumer Health News Source Type: news

" At Your Service " Model to Help Pharma Be More Patient-Focused
In conclusion, Gerow stresses that this model fits a  21st century approach to doing business and the results speak for themselves. He recommends that companies carry out a pilot study to test the model, and is confident that they will find it is valued by doctors, lines up with their mission statements, and has a positive impact on the bottom line. “I f we can get closer to customers and provide something that they value while delivering great medicines to patients,” he asks “how could this not be the model of the future?”To learn more about the role of the service rep, download &nbs...
Source: EyeForPharma - September 6, 2016 Category: Pharmaceuticals Authors: Nicola Davies Source Type: news

FDA Approves New Biological Drug for Rheumatoid Arthritis
Title: FDA Approves New Biological Drug for Rheumatoid ArthritisCategory: Health NewsCreated: 8/31/2016 12:00:00 AMLast Editorial Review: 9/1/2016 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - September 1, 2016 Category: Rheumatology Source Type: news

FDA approves new biological drug for rheumatoid arthritis
HealthDay News A new biological drug to treat rheumatoid arthritis and other inflammatory diseases has been approved by the U.S. Food and Drug Administration. (Source: Health News - UPI.com)
Source: Health News - UPI.com - August 31, 2016 Category: Consumer Health News Source Type: news

FDA Approves New Biological Drug for Rheumatoid Arthritis
WEDNESDAY, Aug. 31, 2016 -- A new biological drug to treat rheumatoid arthritis and other inflammatory diseases has been approved by the U.S. Food and Drug Administration. The drug Erelzi (etanercept-szzs) is a " biosimilar " to Enbrel (etanercept),... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 31, 2016 Category: Journals (General) Source Type: news

FDA Approves Erelzi Biosimilar for Enbrel
WEDNESDAY, Aug. 31, 2016 -- A new biological drug to treat rheumatoid arthritis and other inflammatory diseases has been approved by the U.S. Food and Drug Administration. The drug Erelzi (etanercept-szzs) is a " biosimilar " to Enbrel (etanercept),... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 31, 2016 Category: Journals (General) Source Type: news

FDA OKs Biosimilar to Etanercept for Inflammatory Diseases FDA OKs Biosimilar to Etanercept for Inflammatory Diseases
Erelzi, a biosimilar to Enbrel, treats rheumatoid arthritis, among other disorders. It comes with a boxed warning about the risk for serious infections such as tuberculosis.FDA Approvals (Source: Medscape Pediatrics Headlines)
Source: Medscape Pediatrics Headlines - August 30, 2016 Category: Pediatrics Tags: Rheumatology News Alert Source Type: news

Ultrasound Guidance Does Not Improve RA Treatment Outcomes Ultrasound Guidance Does Not Improve RA Treatment Outcomes
Treating rheumatoid arthritis (RA) based on structured ultrasound assessment does not improve outcomes compared to a conventional tight control strategy based on clinical assessments, according to a new randomized controlled trial.Reuters Health Information (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - August 30, 2016 Category: Orthopaedics Tags: Rheumatology News Source Type: news

Steroid treatments for arthritis 'may be possible with fewer side effects'
This study was mostly focused on application in the treatment of Addison's disease and congenital adrenal hyperplasia, but the researchers stated that with further development, it could lead to improved therapies for other conditions that respond to steroid treatment, includingrheumatoid arthritis and asthma. Dr Mark Nixon of the British Heart Foundation Centre for Cardiovascular Science at the University of Edinburgh said:"The discovery of this selective corticosterone pump in fat cells could lead to a completely new approach in our search for safer steroid medications." The Arthritis Research UK view Dr Nat...
Source: Arthritis Research UK - August 22, 2016 Category: Rheumatology Source Type: news

Clinical Trials of New Drugs for the Treatment of RA Clinical Trials of New Drugs for the Treatment of RA
This article discusses the classification criteria for early rheumatoid arthritis and looks at alternative methods to evaluate disease activity in RA clinical trials.Annals of the Rheumatic Diseases (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - August 22, 2016 Category: Orthopaedics Tags: Rheumatology Journal Article Source Type: news

UC San Diego researchers find new critical role of IL-1beta
Researchers of University of California (UC) San Diego School of Medicine in the US have found that patients suffering from rheumatoid arthritis and taking medications that inhibit interleukin-1beta (IL-1beta) are 300 times more likely to experience … (Source: Drug Development Technology)
Source: Drug Development Technology - August 21, 2016 Category: Pharmaceuticals Source Type: news

CME Outfitters Launches a New Medical Simulation on Rheumatoid...
CME Outfitters launches new medical simulation on The Management of Comorbid Conditions in Patients with Rheumatoid Arthritis(PRWeb August 19, 2016)Read the full story at http://www.prweb.com/releases/2016/08/prweb13626345.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - August 19, 2016 Category: Pharmaceuticals Source Type: news

Flesh-eating infections in rheumatoid arthritis patients spur new discovery
Rheumatoid arthritis patients taking medications that inhibit interleukin-1beta, a molecule that stimulates the immune system, are 300 times more likely to experience invasive Group A Streptococcal infections than patients not on the drug, according to researchers. Their study also uncovers a critical new role for IL-1beta as the body's independent early warning system for bacterial infections. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - August 19, 2016 Category: Science Source Type: news

Self-Reported Flares Predict Damage in Rheumatoid Arthritis
No abstract available (Source: Lippincott's Bone and Joint Newsletter)
Source: Lippincott's Bone and Joint Newsletter - August 19, 2016 Category: Orthopaedics Tags: CME Article Source Type: news

Flesh-eating infections in rheumatoid arthritis patients spur new discovery
(University of California - San Diego) Rheumatoid arthritis patients taking medications that inhibit interleukin-1beta, a molecule that stimulates the immune system, are 300 times more likely to experience invasive Group A Streptococcal infections than patients not on the drug, according to University of California San Diego School of Medicine researchers. Their study, published Aug. 19 in Science Immunology, also uncovers a critical new role for IL-1beta as the body's independent early warning system for bacterial infections. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - August 19, 2016 Category: Infectious Diseases Source Type: news

Report: First-in-class pipeline to address unmet needs of rheumatoid arthritis
Improved treatment options to cover unmet needs of rheumatoid arthritis patients can be provided by first-in-class product innovation, states a new report from GBI Research. (Source: Drug Development Technology)
Source: Drug Development Technology - August 18, 2016 Category: Pharmaceuticals Source Type: news

Court rules Remicade patent is invalid
The U.S. District Court in Massachusetts Federal Court has ruled a patent for Remicade, a top-selling rheumatoid arthritis drug sold by Johnson& Johnson subsidiary Janssen Biotech, is invalid. The court sided with the request for a summary judgement in the patent infringement dispute filed by Celltrion Healthcare Co. Ltd and Pfizer-owned Hospira Healthcare Corp., which want to sell a biosimilar version of the product. Johnson& Johnson (NYSE; JNJ) issued a statement following the ruling in which … (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 17, 2016 Category: Pharmaceuticals Authors: John George Source Type: news

8 Yoga Poses That Will Help Ease Chronic Pain
Yoga can be an excellent way to release anxiety, but perhaps one of its more underrated benefits is the magic it can do for chronic pain. Those who suffer from conditions like rheumatoid arthritis can reap the perks from the gentle motions of a yoga practice. And thankfully Happify, a website and app dedicated to helping people build skills for happiness through science-based activities and games, collected a few poses that are known to help ease aches in the infographic below. Take a look at the instructions and give them a try the next time you’re needing some relief. It’s time to send that pain packing. ―L...
Source: Healthy Living - The Huffington Post - August 15, 2016 Category: Consumer Health News Source Type: news

Epigenetics: The Keeper of the Code
In recent years, attention has increasingly turned away from DNA's code and toward the way that DNA is packaged and the proteins that interact with it. These so-called epigenetic factors are heritable, reversible, and hugely influential. Over the past few decades, epigenetics has become a hot scientific topic. With potential roles in cancer, neuropsychiatric disorders, and immune disorders, it is no surprise that epigenetics is garnering such intense attention. The way in which genes are expressed is incredibly complex; it requires the infinitely detailed coordination of multiple molecular players. Epigenetics creates...
Source: Healthy Living - The Huffington Post - August 12, 2016 Category: Consumer Health News Source Type: news

Mesoblast Cell Treatment Shows Promise in Rheumatoid Arthritis -Study Mesoblast Cell Treatment Shows Promise in Rheumatoid Arthritis -Study
Mesoblast Ltd on Monday said its experimental stem-cell treatment led to significant improvements of symptoms and disease activity in patients whose rheumatoid arthritis had stopped being helped by widely used biotech medicines, according to data from a mid-stage trial.Reuters Health Information (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - August 10, 2016 Category: Orthopaedics Tags: Rheumatology News Source Type: news

The Latest in Lupus, Arthritis, and Ankylosing Spondylitis The Latest in Lupus, Arthritis, and Ankylosing Spondylitis
A productive meeting in London yields important new results in rheumatoid arthritis, ankylosing spondylitis, and lupus. Dr Ioannis Parodis gives an overview of his top studies.Medscape Rheumatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 10, 2016 Category: Consumer Health News Tags: Rheumatology Viewpoint Source Type: news

The Efficacy and Safety of CT-P13 vs Infliximab in RA The Efficacy and Safety of CT-P13 vs Infliximab in RA
CT-P13, a biosimilar of reference infliximab, may be a safe and effective treatment option for patients with active rheumatoid arthritis.Arthritis Research & Therapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 9, 2016 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Promising rheumatoid arthritis therapy sarilumab accepted for EU review
A potentially promising new treatment for rheumatoidarthritis has just passed an important milestone on its path to regulatory approval. Sarilumab, a human monoclonal antibody intended for the treatment of adults with moderate to severely activerheumatoid arthritis, has had its marketing authorisation application accepted by the European Medicines Agency (EMA), bringing it one step closer to widespread availability. The benefits of the new therapy Developed by Sanofi and Regeneron Pharmaceuticals, sarilumab works by targeting the IL-6 receptor, which is known to play a key role in the joint damage and painful symptoms that...
Source: Arthritis Research UK - August 8, 2016 Category: Rheumatology Source Type: news

Mesoblast cell treatment shows promise in rheumatoid arthritis : study
(Reuters) - Mesoblast Ltd on Monday said its experimental stem-cell treatment led to significant improvements of symptoms and disease activity in patients whose rheumatoid arthritis had stopped being helped by widely used biotech medicines, according to data from a mid-stage trial. (Source: Reuters: Health)
Source: Reuters: Health - August 8, 2016 Category: Consumer Health News Tags: healthNews Source Type: news

New arthritis jab ‘will relieve pain for acute sufferers’
A NEW fortnightly injection could provide relief from the crippling pain of rheumatoid arthritis, it was revealed yesterday. (Source: Daily Express - Health)
Source: Daily Express - Health - August 8, 2016 Category: Consumer Health News Source Type: news

How Much Omega-3 vs Omega-6
All the so-called “nutrition experts” telling us to eat unsaturated fats instead of saturated fats are missing the point. There are natural saturated fats that are perfectly healthy to eat… and manufactured unsaturated fats that are at the root cause of many of our health problems. That’s because it’s the ratio of omega-6 fats and omega-3 fats in our modern diet that’s actually the problem. Let me explain… Omega Fatty Acids In Our Diet Omega-6s are fatty acids commonly found in vegetable oils. That includes safflower, sunflower, corn, cottonseed, sesame and soybean. They’re...
Source: Al Sears, MD Natural Remedies - August 8, 2016 Category: Complementary Medicine Authors: Al Sears Tags: Nutrition Source Type: news

Well: Arthritis Drug May Have Benefits Against Alzheimer ’ s
An inflammation-fighting drug for rheumatoid arthritis may offer protection against Alzheimer ’ s, a study suggests. (Source: NYT Health)
Source: NYT Health - August 4, 2016 Category: Consumer Health News Authors: NICHOLAS BAKALAR Tags: Alzheimer's Disease Featured Live Source Type: news

Generic biosimilar therapies for arthritis 'as effective as branded versions'
This study only applies to anti-TNFs, underlining the need for further research on whether other biosimilar products - such as biosimilar insulins - work as well as their branded counterparts. Nevertheless, the results show that rheumatoid arthritis patients at least can benefit from the availability of effective therapy options at a lower cost, meaning more people may be able to access the drugs without placing an excessive burden on healthcare services. Study leader Dr Caleb Alexander, co-director of the Johns Hopkins Center for Drug Safety and Effectiveness, said:"Hopefully this will encourage the brisk adoption of...
Source: Arthritis Research UK - August 2, 2016 Category: Rheumatology Source Type: news

Self-Reported Flares Predict Radiographic Progression in RA Self-Reported Flares Predict Radiographic Progression in RA
Are flares reported by rheumatoid arthritis patients predictors of radiographic progression?Arthritis Research & Therapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 2, 2016 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

' Generic' biologic drugs appear comparable to brand-name counterparts
Generic forms of a biologic drug used to treat rheumatoid arthritis, inflammatory bowel disease and psoriasis appear to be as safe and effective as their brand-name counterparts, a new analysis suggests. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - August 1, 2016 Category: Science Source Type: news

Rheumatoid arthritis: Can it affect the eyes?
Although rheumatoid arthritis is primarily a joint disease, it occasionally affects the eyes. (Source: MayoClinic.com - Ask a Specialist)
Source: MayoClinic.com - Ask a Specialist - August 1, 2016 Category: Consumer Health News Source Type: news

Potential new way to sway the immune system
A new international collaboration opens a door to influencing the immune system, which would be useful to boost the effectiveness of vaccines or to counter autoimmune diseases such as lupus and rheumatoid arthritis. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - August 1, 2016 Category: Science Source Type: news

Generic Biologic Drugs Seem as Effective as Originals
MONDAY, Aug. 1, 2016 -- Generic biologic drugs are similarly effective to brand-name counterparts in treating rheumatoid arthritis, inflammatory bowel disease and psoriasis, a new study says. Biologics are medications made from living cells. They... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 1, 2016 Category: Journals (General) Source Type: news

Found: A potential new way to sway the immune system
(Scripps Research Institute) A new international collaboration involving scientists at The Scripps Research Institute opens a door to influencing the immune system, which would be useful to boost the effectiveness of vaccines or to counter autoimmune diseases such as lupus and rheumatoid arthritis. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - August 1, 2016 Category: Biology Source Type: news

Synthetic vaccine particles immune tolerance mechanism published in Nature Nanotechnology
(The Yates Network) Preclinical studies show that Selecta Biosciences' proprietary immune therapies use a targeted mechanism of action to improve the efficacy and safety of biologic therapeutics and to address autoimmune diseases and allergies. The company is developing targeted antigen-specific immune therapies for rare and serious diseases. The data in Nature Nanotechnology support Selecta's lead clinical program, showing Selecta's SVP-Rapamycin induces antigen-specific immune tolerance and prevents the formation of anti-drug antibodies to biologic drugs, including pegsiticase (gout) and adalimumab (rheumatoid arthritis)...
Source: EurekAlert! - Cancer - August 1, 2016 Category: Cancer & Oncology Source Type: news

Amgen 2nd-quarter profit tops Street view, raises 2016 forecast
(Reuters) – Amgen (NSDQ:AMGN) on Wednesday reported higher-than-expected 2nd-quarter profit on increased sales of its blockbuster rheumatoid arthritis drug Enbrel and newer medicines, and the company again raised its full-year forecast. The forecast appeared to signal management’s confidence in the 2nd half of the year. The company is on track to meet or exceed its long-term objectives,” Chief Executive Robert Bradaway said in a statement. Amgen said it now expects 2016 adjusted earnings per share of $11.10 to $11.40, up from its prior view of $10.85 to $11.20. Its midpoint is above of Wall...
Source: Mass Device - July 27, 2016 Category: Medical Equipment Authors: MassDevice Tags: Business/Financial News Drug-Device Combinations Amgen Source Type: news

CHMP Backs Abatacept (Orencia) for MTX-Naive Patients With RA CHMP Backs Abatacept (Orencia) for MTX-Naive Patients With RA
The EMA's Committee for Medicinal Products for Human Use recommended marketing authorization for abatacept in combination with methotrexate for methotrexate-naive adults with rheumatoid arthritis. International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 26, 2016 Category: Consumer Health News Tags: Rheumatology News Alert Source Type: news

Concordance With the ACR RA Treatment Recommendations Concordance With the ACR RA Treatment Recommendations
Which factors may influence the use of DMARDs in rheumatoid arthritis? Are treatment patterns consistent with the published recommendations? Arthritis Research & Therapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 26, 2016 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

NHS too slow helping people with inflammatory arthritis
The  NHS is failing to assess people with rheumatoid and early inflammatory arthritis quickly enough, a clinical audit has shown. Rheumatoid arthritis (and other forms of  early or inflammatory arthritis, or EIA)  are conditions in which the immune system attacks the joints, making them inflamed   & ndash; hot, red, painful and swollen. These conditions can lead to long term joint damage causing pain and disability. Urgent, intensive treatment is needed when these conditions occur to stop inflammation and prevent long-term damage. Published on 25 July 2016, the audit is now in its ...
Source: Arthritis Research UK - July 24, 2016 Category: Rheumatology Source Type: news

Experts criticise arthritis patient referral delays
Just a fifth of patients are referred by GPs quickly enough Related items from OnMedica 40% of European patients unlikely to access RA drugs Arthritis patients wait too long for referral RA risk lower after urinary and gut infections Drug for rheumatoid arthritis appears to have effect on severe eczema (Source: OnMedica Latest News)
Source: OnMedica Latest News - July 24, 2016 Category: UK Health Source Type: news